Abstract
Congenital fibrinogen deficiency is an inherited disorder due to genetic mutations with diverse presentations arising from reduced fibrinogen levels (hypofibrinogenemia), absence of fibrinogen in circulation (afibrinogenemia), abnormal functioning (dysfibrinogenemia) or both reduced levels and abnormal functioning (hypodysfibrinogenemia) of fibrinogen. The decreased fibrinogen concentration in congenital fibrinogen deficiency necessitates fibrinogen replacement therapy with fresh frozen plasma, cryoprecipitate, or human fibrinogen concentrate. However, the use of fresh frozen plasma and cryoprecipitate is limited owing to their longer transfusion time, requirement of high doses, volume overload, risk of viral transmission, and other safety concerns. The availability of human fibrinogen concentrate has made it the preferred replacement alternative due to its reduced risk of viral transmission, smaller infusion volume, and accurate dosing. The hemostatic efficacy and safety of human fibrinogen concentrate in congenital fibrinogen deficiency is well established in the literature. We review the prevalence of congenital fibrinogen deficiency in India and the current role of human fibrinogen concentrate in its management.
References
1.
Tziomalos
K
, Vakalopoulou
S
, Perifanis
V
, Garipidou
V
. Treatment of congenital fibrinogen deficiency: overview and recent findings
. Vasc Health Risk Manag
. 2009
;5
:843
–8
. .2.
Tiscia
GL
, Margaglione
M
. Human fibrinogen: molecular and genetic aspects of congenital disorders
. Int J Mol Sci
. 2018
;19
(6
):1597
. .3.
Peyvandi
F
. Epidemiology and treatment of congenital fibrinogen deficiency
. Thromb Res
. 2012
;130
(Suppl 2
):S7
–11
. .4.
Acharya
SS
, Dimichele
DM
. Rare inherited disorders of fibrinogen
. Haemophilia
. 2008
;14
(6
):1151
–8
. .5.
Besser
MW
, MacDonald
SG
. Acquired hypofibrinogenemia: current perspectives
. J Blood Med
. 2016
;7
:217
–25
. .6.
Awasthy
N
, Aggarwal
KC
, Gupta
H
, Saluja
S
. Congenital hypofibrinogenemia
. Indian Pediatr
. 2004
;41
(2
):185
–7
.7.
Chandan
GD
, Annaji
AG
, Bhatnagar
S
, Mohandas
U
, Dave
P
. Cellulitis on face in a patient with congenital afibrinogenemia
. J Indian Soc Pedod Prev Dent
. 2011
;29
(1
):46
–9
. .8.
Hariharan
G
, Ramachandran
S
, Parapurath
R
. Congenital afibrinogenemia presenting as antenatal intracranial bleed: a case report
. Ital J Pediatr
. 2010
;36
(1
):1
. .9.
Goyal
SS
, Bhardwaj
DV
, Shenoy
U
, Reddy
B
. Anaesthetic management of a child with congenital afibrinogenemia: a rare inherited coagulation disorder
. Indian J Anaesth
. 2011
;55
(6
):605
. .10.
Mehta
S
, Mehta
S
, Malhotra
H
, Sharma
U
, Varma
A
. Congenital afibrinogenaemia
. J Assoc Physicians India
. 1989
;37
(10
):668
–9
.11.
Gadagi
JS
, Chava
VK
. Diagnosis and non-surgical periodontal management in congenital afibrinogenemia: report of a rare case
. J Investig Clin Dent
. 2012
;3
(3
):232
–5
.12.
Patra
S
, Reddy
B
, Nagesh
C
, Srinivas
B
, Manjunath
C
. Recurrent myocardial infarction in a case of congenital afibrinogenemia
. Heart Views
. 2014
;15
(1
):16
. .13.
Jain
K
, Parande
A
. Congenital afibrinogenemia (a case report)
. J Assoc Physicians India
. 1962
;10
:741
–4
.14.
Rani
TR
, Gopinath
R
. An unusual cause of a prolonged activated coagulation time during cardiac surgery: congenital hypofibrinogenemia
. J Cardiothorac Vasc Anesth
. 2008
;22
(22
):725
–6
. .15.
Madhusudhan
B
, Mahendra
J
, Rohan
M
, Srinivasa
R
. Hematomyelia as a cause of Brown-Sequard’s syndrome in a hypofibrinogenemic patient
. Neurol India
. 2014
;62
(4
):473
. .16.
Kaur
M
, Kumar
N
, Bose
SK
, Rajendran
A
, Trehan
A
, Ahluwalia
J
. Congenital afibrinogenemia in a new born: a rare cause for bleeding
. Blood Coagul Fibrinolysis
. 2014
;25
(5
):527
–9
. .17.
Sumitha
E
, Jayandharan
GR
, Arora
N
, Abraham
A
, David
S
, Devi
GS
, Molecular basis of quantitative fibrinogen disorders in 27 patients from India
. Haemophilia
. 2013
;19
(4
):611
–8
. .18.
Shetty
S
, Shelar
T
, Mirgal
D
, Nawadkar
V
, Pinto
P
, Shabhag
S
, Rare coagulation factor deficiencies: a countrywide screening data from India
. Haemophilia
. 2014
;20
(4
):575
–81
. .19.
Weisel
JW
, Litvinov
RI
. Fibrin formation, structure and properties
. Subcell Biochem
. 2017
;82
:405
–56
. .20.
Fries
D
, Martini
WZ
. Role of fibrinogen in trauma-induced coagulopathy
. Br J Anaesth
. 2010
;105
(2
):116
–21
. .21.
Asselta
R
, Duga
S
, Tenchini
ML
. The molecular basis of quantitative fibrinogen disorders
. J Thromb Haemost
. 2006
;4
(10
):2115
–29
. .22.
Kattula
S
, Byrnes
JR
, Wolberg
AS
. Fibrinogen and fibrin in hemostasis and thrombosis
. Arterioscler Thromb Vasc Biol
. 2017
;37
(3
):e13
–21
. .23.
Levy
JH
, Szlam
F
, Tanaka
KA
, Sniecienski
RM
. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding
. Anesth Analg
. 2012
;114
(2
):261
–74
. .24.
Levy
JH
, Szlam
F
, Tanaka
KA
, Sniecienski
RM
. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding
. Anesth Analg
. 2012
;114
(2
):261
–74
. .25.
Stang
LJ
, Mitchell
LG
. Fibrinogen
. Methods Mol Biol
. 2013
;992
:181
–92
. .26.
Miesbach
W
, Schenk
J
, Alesci
S
, Lindhoff-Last
E
. Comparison of the fibrinogen clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia
. Thromb Res
. 2010
;126
:e428
–33
. .27.
Al-Mondhiry
H
, Ehmann
WC
. Congenital afibrinogenemia
. Am J Hematol
. 1994
;46
(4
):343
–7
. .28.
Kannel
WB
, Wolf
PA
, Castelli
WP
, D’Agostino
RB
. Fibrinogen and risk of cardiovascular disease. The Framingham Study
. JAMA
. 1987
;258
(9
):1183
–6
. .29.
Dean
M
, Bandler
L
, Bowden
DK
, Duggan
J
, Farmer
S
, French
C
, Patient blood management guidelines: module 3 medical
. 2013
.30.
Peyvandi
F
, Palla
R
, Menegatti
M
, Siboni
SM
, Halimeh
S
, Faeser
B
, Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European network of rare bleeding disorders
. J Thromb Haemost
. 2012
;10
(4
):615
–21
. .31.
Liumbruno
GM
, Bennardello
F
, Lattanzio
A
, Piccoli
P
, Rossetti
G
. Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period
. Blood Transfus
. 2011
;9
(2
):189
–217
. .32.
Kozek-Langenecker
SA
, Afshari
A
, Albaladejo
P
, Santullano
CA
, De Robertis
E
, Filipescu
DC
, Management of severe perioperative bleeding: guidelines from the European society of anaesthesiology
. Eur J Anaesthesiol
. 2013
;30
(6
):270
–382
. .33.
Spahn
DR
, Bouillon
B
, Cerny
V
, Coats
TJ
, Duranteau
J
, Fernández-Mondéjar
E
, Management of bleeding and coagulopathy following major trauma: an updated European guideline
. Crit Care
. 2013
;17
(2
):R76
. .34.
Fries
D
, Innerhofer
P
, Perger
P
, Gütl
M
, Heil
S
, Hofmann
N
, [Coagulation management in trauma-related massive bleeding. Recommendations of the task force for coagulation (AGPG) of the Austrian society of anesthesiology, resuscitation and intensive care medicine (OGARI)]
. Anasthesiol Intensivmed Notfallmed Schmerzther
. 2010
;45
(9
):552
–61
. .35.
Stanworth
SJ
. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy
. Hematology Am Soc Hematol Educ Program
. 2007
:179
–86
. .36.
Chairman
B
, nominee
C
, Bolton-Maggs
P
, nominee
M
, nominee
D
, nominee
L
. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant
. Br J Haematol
. 2004
;126
:11
–28
.37.
Chowdary
P
, Saayman
AG
, Paulus
U
, Findlay
GP
, Collins
PW
. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients
. Br J Haematol
. 2004
;125
(1
):69
–73
. .38.
Mannucci
PM
, Duga
S
, Peyvandi
F
. Recessively inherited coagulation disorders
. Blood
. 2004
;104
(5
):1243
–52
. .39.
Nascimento
B
, Goodnough
LT
, Levy
JH
. Cryoprecipitate therapy
. Br J Anaesth
. 2014
;113
(6
):922
–34
. .40.
Wong
H
, Curry
N
. Cryoprecipitate transfusion: current perspectives
. Int J Clin Transfus Med
. 2016
;4
:89
–97
.41.
Sørensen
B
, Bevan
D
. A critical evaluation of cryoprecipitate for replacement of fibrinogen
. Br J Haematol
. 2010
;149
(6
):834
–43
. .42.
Hanna
JM
, Keenan
JE
, Wang
H
, Andersen
ND
, Gaca
JG
, Lombard
FW
, Use of human fibrinogen concentrate during proximal aortic reconstruction with deep hypothermic circulatory arrest
. J Thorac Cardiovasc Surg
. 2016
;151
(2
):376
–82
. .43.
Schulz
PM
, Gehringer
W
, Nöhring
S
, Müller
S
, Schmidt
T
, Kekeiss-Schertler
S
, Biochemical characterization, stability, and pathogen safety of a new fibrinogen concentrate (fibryga®)
. Biologicals
. 2018
;52
:72
–7
.44.
de Moerloose
P
, Neerman-Arbez
M
. Treatment of congenital fibrinogen disorders
. Expert Opin Biol Ther
. 2008
;8
(7
):979
–92
. .45.
Bolton-Maggs
PH
, Perry
DJ
, Chalmers
EA
, Parapia
LA
, Wilde
JT
, Williams
MD
, The rare coagulation disorders: review with guidelines for management from the United Kingdom haemophilia centre doctors’ organisation
. Haemophilia
. 2004
;10
(5
):593
–628
. .46.
Costa-Filho
R
, Hochleitner
G
, Wendt
M
, Teruya
A
, Spahn
DR
. Over 50 years of fibrinogen concentrate
. Clin Appl Thromb Hemost
. 2016
;22
(2
):109
–14
. .47.
Fries
D
, Krismer
A
, Klingler
A
, Streif
W
, Klima
G
, Wenzel
V
, Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model
. Br J Anaesth
. 2005
;95
(2
):172
–7
. .48.
Fries
D
, Innerhofer
P
, Reif
C
, Streif
W
, Klingler
A
, Schobersberger
W
, The effect of fibrinogen substitution on reversal of dilutional coagulopathy: an in vitro model
. Anesth Analg
. 2006
;102
(2
):347
–51
. .49.
RiaSTAP fibrinogen concentrate (human) lyophilized powder for solution for intravenous injection
. Kankakee, IL
: CSL Behring LLC
; 2020 Jul
.50.
Fibrogen-I™
. Freeze dried powder, manufactured from human plasma. Pacakge insert
. Ahmedabad
: Intas Pharmaceuticals Limited
.51.
Lissitchkov
T
, Madan
B
, Djambas Khayat
C
, Zozulya
N
, Ross
C
, Karimi
M
, Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients
. J Thromb Haemost
. 2020
;18
(4
):815
–24
. .52.
Lasky
J
, Teitel
J
, Wang
M
, Dalton
D
, Schmidt
DS
, Brainsky
A
. Fibrinogen concentrate for bleeding in patients with congenital fibrinogen deficiency: observational study of efficacy and safety for prophylaxis and treatment
. Res Pract Thromb Haemost
. 2020
;4
(8
):1313
–23
.53.
Négrier
C
, Rothschild
C
, Borg
J-Y
, Lambert
T
, Claeyssens
S
, Sanhes
L
, Post-authorization safety study of Clottafact®, a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study
. Vox Sang
. 2016
;111
(4
):383
–90
.54.
Djambas Khayat
C
, El Khorassani
M
, Lambert
T
, Gay
V
, Barthez-Toullec
M
, Lamazure
J
, Clinical pharmacology, efficacy and safety study of a triple-secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency
. J Thromb Haemost
. 2019
;17
(4
):635
–44
. .55.
Bornikova
L
, Peyvandi
F
, Allen
G
, Bernstein
J
, Manco-Johnson
MJ
. Fibrinogen replacement therapy for congenital fibrinogen deficiency
. J Thromb Haemost
. 2011
;9
(9
):1687
–704
. .56.
Kreuz
W
, Meili
E
, Peter-Salonen
K
, Haertel
S
, Devay
J
, Krzensk
U
, Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency
. Transfus Apher Sci
. 2005
;32
(3
):247
–53
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
